Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Capivasertib by AstraZeneca for Hormone-Sensitive Prostate Cancer: Likelihood of Approval
Capivasertib is under clinical development by AstraZeneca and currently in Phase III for Hormone-Sensitive Prostate Cancer. According to GlobalData, Phase...